The first clinical study was carried out on melanoma by Baldi and colleagues (8), who found significant HtrA1 upregulation in the primary tumor compared with metastases, and suggested that HtrA1 expression could be an indicator of disease progression. Here, HTRA1 is linked to melanoma.